Combining Transfection and Immunotherapy in Preclinical Research
The combination of advanced gene delivery methods, such as transfection, with immunotherapy research has opened exciting new horizons for treating blood cancers. Immunotherapy harnesses the patient’s immune system to target and eliminate malignant cells, often through engineered immune cells or immune checkpoint modulation.
Transfection techniques allow scientists to genetically modify immune cells, such as T lymphocytes, natural killer (NK) cells, or dendritic cells, to enhance their anti-cancer capabilities. For example, electroporation can be used to introduce chimeric antigen receptor (CAR) constructs into T cells, enabling them to recognize specific surface markers on leukemia or lymphoma cells.
This non-viral gene delivery method offers advantages including reduced risk of insertional mutagenesis, transient expression that allows rapid iteration of constructs, and cost-effectiveness compared to viral vectors. Furthermore, transient transfection facilitates safety testing by limiting prolonged immune activation.
Beyond CAR-T cell development, transfection is used to modify immune checkpoint molecules, cytokine expression, or resistance pathways in immune cells and cancer cells alike. These modifications can improve immune cell trafficking, persistence, and tumor-killing efficiency.
In preclinical models, combining transfected immune cells with leukemia or lymphoma xenografts enables comprehensive evaluation of therapeutic efficacy, immune cell infiltration, and cytokine release profiles. These studies help optimize immunotherapy design and predict potential side effects.
The synergy between gene delivery and immunotherapy technologies is accelerating the translation of personalized, effective blood cancer treatments from bench to bedside.
References: Altogen.com Altogenlabs.com